MedGenome, Inc., headquartered in Silicon Valley, is a leading provider of genomic solutions with a mission to improve global health by developing deep insights into diseases at the genetic and molecular level.
MedGenome’s genomic technologies and big data analytics advance the understanding of the genetic basis of cancer and include advanced immuno-oncology solutions to
identify biomarkers for patient selection, monitor durability of response and evaluate mechanisms of drug unresponsiveness and resistance. Medgenome’s neoepitope prioritization analysis service accelerates the discovery of cancer vaccine candidates. Compatible with any tumor model, we combine proprietary T cell receptor and HLA binding prediction for increased specificity and accuracy of prioritized neoepitopes. MedGenome operates a CLIA certified, CAP accredited next generation sequencing facility in Foster City, CA and the highest throughput NGS lab in Southeast Asia for clinical diagnostics. We additionally are a founding member of GenomeAsia 100K to sequence 100K Asian individuals’ genomes.